Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: A tissue Doppler study

Acta Cardiologica

Volumn 65, Issue 4, 2010, Pages 401-406

  Ordu, Serkan ^a   Ozhan, Hakan ^a   Alemdar, Recai ^a   Aydin, Mesut ^a   Basar, Cengiz ^a   Caglar, Onur ^a   Yazici, Mehmet ^a   Yalcin, Subhan ^a  

^a DUZCE UNIVERSITY   (Turkey)

Author keywords

Diastolic function; Pioglitazone; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; AORTA; ARTICLE; BLOOD FLOW VELOCITY; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DECELERATION; DIABETIC PATIENT; DIASTOLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART CONTRACTION; HEART MUSCLE RELAXATION; HEART VENTRICLE EJECTION TIME; HEART VENTRICLE FUNCTION; HEART VENTRICLE WALL; HEART VOLUME; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; MITRAL VALVE; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLE; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TREATMENT OUTCOME; TRICUSPID VALVE; WAVEFORM; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECTS; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATHOPHYSIOLOGY;

BLOOD FLOW VELOCITY; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; SYSTOLE; THIAZOLIDINEDIONES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 78049245845     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.65.4.2053898     Document Type: Article

References (21)

1. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-39. (Pubitemid 34517172)
2. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, Lee ET, Devereux RB. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001; 37: 1943-9. (Pubitemid 32499984)
3. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54: 778-82.
4. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-23. (Pubitemid 41103346)
5. Tsuji T, Mizushige K, Noma T, Murakami K, Ohmori K, Miyatake A, Kohno M. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001; 38: 868-74.
6. Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003; 19: 487-93.
7. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, Kawano Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18: 949-57. (Pubitemid 41040266)
8. Henry WL, DeMaria A, Gramiak R, King DL, Kisslo JA, Popp RL, Sahn DJ, Schiller NB, Tajik A, Teichholz LE, Weyman AE. Report of the American society of echocardiography committee on nomenclature and standards in twodimensional imaging. Circulation 1980: 62: 212-7. (Pubitemid 10035638)
9. Pitale SU, Abraira C, Emanuele NV, McCarren M, Henderson WG, Pacold I, Bushnell D, Colwell JA, Nuttall FQ, Levin SR, Sawin CT, Comstock JP, Silbert CK. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 2000; 23: 1316-20.
10. Brand FN, Kannel WB, Evans J, Larson MG, Wolf PA. Glucose intolerance, physical signs of peripheral artery disease, and risk of cardiovascular events: the Framingham Study. Am Heart J 1998; 136: 919-27. (Pubitemid 28506894)
11. Lind L, Andersson PE, Andrén B, Hänni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13: 433-8.
12. Kamide K, Nagano M, Nakano N, Yo Y, Kobayashi R, Rakugi H, Higaki J, Ogihara T. Insulin resistance and cardiovascular complications in patients with essential hypertension. Am J Hypertens 1996; 9: 1165-71. (Pubitemid 26423639)
13. Miyazato J, Horio T, Takishita S, Kawano Y. Fasting plasma glucose is an independent determinant of left ventricular diastolic dysfunction in nondiabetic patients with treated essential hypertension. Hypertens Res 2002; 25: 403-9. (Pubitemid 34752560)
14. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405-12.
15. Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82: 848-55.
16. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907. (Pubitemid 30117886)
17. Terui G, Goto T, Katsuta M, Aoki I. Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients. J Cardiol 2006; 48: 263-7.
18. Shargorodsky M,Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16: 617-22. (Pubitemid 36900582)
19. Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008; 10: 206-12.
20. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007; 30: 387-94.
21. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-89.